Significant Ownership of ASTRAZENECA PLC

Signature - Title
/s/ Matthew Bowden - Matthew Bowden / Company Secretary
Location
Cambridge
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by ASTRAZENECA PLC.

Notify me when ASTRAZENECA PLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of ASTRAZENECA PLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CLLS Cellectis S.A. Ordinary shares, nominal value of EUR0.05 per ordinary share 44% $66,440,000 44,000,000 AstraZeneca PLC 23 Jan 2025
Innate Pharma SA Ordinary Shares, EUR0.05 nominal value per share 8.3% 7,825,501 AstraZeneca PLC 22 Dec 2025
MNPR Monopar Therapeutics Inc. Common Stock, $0.001 par value per share 7.8% $34,126,392 522,667 AstraZeneca PLC 31 Dec 2025
CDT Conduit Pharmaceuticals Inc. Common Stock, par value $0.0001 per share 1.1% $3,340 73,892 AstraZeneca PLC 31 Mar 2025

Schedules 13D/G Reported by ASTRAZENECA PLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.